Drissa Makan Toure

Dr. Drissa Makan Toure

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2022 in Journal of Social Service Research
Verified
Journal Article
Closed access
DTDrissa Makan Toure
Drissa Makan Toure
Gaurav KumarGaurav Kumar
Gaurav Kumar
CWCady Walker
Cady Walker
JTJack E. Turman
Jack E. Turman
DSDejun Su
Dejun Su
The Centers for Disease Control and Prevention approximates that 1 in 5 children experience a mental or behavioral health disorder. Pediatric mental healthcare service access cannot be improved without strong coordination between educational settings, social service providers for children, and adequate policy support. Addressing this critical child development issue is dependent on us understanding the barriers to mental healthcare access faced by pediatric populations. This qualitative study explored barriers to pediatric mental healthcare access based on in-depth interviews with 53 key informants representing childcare settings, K-12 schools, foster care settings, and evidence-based home visitation programs. Semi-structured interviews with participants identified barrier-related themes and subthemes. The themes reflect a series of hurdles related to pediatric mental healthcare access including, lack of preparedness/training for pediatric mental health screening and management, limited resources, lack of policy support, transportation, and family issues that have hindered mental health support for children. The findings highlight the compounding barriers to pediatric mental healthcare services and point to opportunities for improving pediatric mental health using a holistic approach. Future research should focus on designing and implementing community and organization-based strategies to break down these barriers for families to optimize their children’s mental health and wellness.

2 September 2025 in Discover Medicine
Verified
Journal Article
Open access
PDF file
AAAhmed Adebowale Adedeji
Ahmed Adebowale Adedeji
IAIsmail Adesina Abdus-Salam
Ismail Adesina Abdus-Salam
AAAminah Adeola Adedeji
Aminah Adeola Adedeji
LOLanre Omotayo
Lanre Omotayo
IOIbrahim Oreagba
Ibrahim Oreagba
DTDrissa Makan Toure
Drissa Makan Toure
Public health pharmacology (PHP) is an emerging interdisciplinary field that integrates pharmacological principles with public health strategies to optimize therapeutic outcomes at the population level. This perspective examines its rationale, significance, and potential impact in addressing pressing healthcare challenges such as antimicrobial resistance (AMR), adverse drug reactions (ADRs), medication access disparities, and chronic disease management. Through a narrative review of existing literature and expert consultations, we explore PHP's distinct role in complementing allied disciplines while addressing systemic gaps in healthcare delivery. This perspective suggests that public health pharmacology could enhance population health and equity outcomes by addressing health disparities and global one health challenges, strengthening pharmacovigilance, and improving the quality and supply of medical products.

8 August 2026 in COVID
Verified
Journal Article
Open access
PDF file
TATaiwo Opeyemi Aremu
Taiwo Opeyemi Aremu
OOOlihe Okoro
Olihe Okoro
CGCaroline Gaither
Caroline Gaither
SBS. Bruce Benson
S. Bruce Benson
DTDrissa Makan Toure
Drissa Makan Toure
Jon SchommerJon Schommer
Jon Schommer
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willingness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State from 7 September to 16 September 2024, using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations using chi-square tests, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer–Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). Respondents were predominantly female (60.6%); the largest age groups were 25–34 (30.2%) and 35–44 (28.4%) years. Overall, 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p = 0.0028; trend p = 0.0002) and religion (p = 0.0403). In adjusted models, respondents aged 45–54 years (aOR 6.54; 95% CI: 1.73–24.79) and 55–64 years (aOR 4.97; 95% CI: 1.05–23.55) had higher odds of acceptance than those aged 18–24 years. Christian affiliation was associated with lower odds than Muslim affiliation (aOR 0.41; 95% CI: 0.20–0.83). Discrimination was acceptable (AUC 0.75; 95% CI: 0.69–0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.

24 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TATaiwo Opeyemi Aremu
Taiwo Opeyemi Aremu
OOOlihe Okoro
Olihe Okoro
CGCaroline Gaither
Caroline Gaither
SBS. Bruce Benson
S. Bruce Benson
DTDrissa Makan Toure
Drissa Makan Toure
Jon SchommerJon Schommer
Jon Schommer
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willing-ness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations with chi-square, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer-Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p=0.0028; trend p=0.0002) and religion (p=0.0403). In adjusted models, respondents aged 45-54 years (AOR 6.54; 95% CI 1.73-24.79) and 55-64 years (AOR 4.97; 95% CI 1.05-23.55) had higher odds of acceptance than those aged 18-24 years. Christian affiliation was associated with lower odds than Muslim affiliation (AOR 0.41; 95% CI 0.20-0.83). Discrimination was acceptable (AUC 0.75; 95% CI 0.69-0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.

11 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TATaiwo Opeyemi Aremu
Taiwo Opeyemi Aremu
OOOlihe Okoro
Olihe Okoro
CGCaroline Gaither
Caroline Gaither
SBS. Bruce Benson
S. Bruce Benson
DTDrissa Makan Toure
Drissa Makan Toure
Jon SchommerJon Schommer
Jon Schommer
Background: During the COVID-19 pandemic, Nigeria relied largely on imported vaccines, underscoring vulnerabilities in supply chains and the absence of domestic vaccine manufacturing. Understanding supply-related barriers and the resources required for local vaccine production is critical for future pandemic preparedness and population health outcome. The objective of the study was to identify stakeholder-perceived barriers to COVID‑19 vaccine manufacturing in Nigeria and to describe the resources and enabling conditions required for local production. Methods: We conducted a qualitative needs assessment using semi-structured interviews with senior personnel from Nigerian pharmaceutical manufacturing firms and regulatory agencies. Participants were recruited purposively and consecutively. Interviews (30-60 minutes) were conducted via Zoom, audio-recorded with consent, transcribed, and analyzed using inductive thematic analysis following established six-phase procedures. Reporting adheres to the Consolidated Criteria for Reporting Qualitative Research (COREQ). Results: Six participants (two regulators and four pharmaceutical executives) identified three interrelated barrier to domestic COVID-19 vaccine production: (1) technical and knowledge gaps (loss of hands-on expertise, absence of operational vaccine manufacturing facilities, limited technology transfer), (2) financial and infrastructure barriers (high cost of capital, serial taxation, unreliable electricity and logistics constraints), and (3) systemic and institutional barriers (inconsistent political commitment, policy discontinuity, regulatory capacity gaps, and concerns about public confidence). To enable local production, participants emphasized coordinated investment in workforce development, technology-transfer partnerships, modern utilities and cold chain systems, access to specialized equipment and high-quality inputs, and predictable policy, financing, and regulatory environments. Conclusions: Participants perceived Nigeria’s current capacity as insufficient for COVID-19 vaccine manufacturing but identified actionable levers, particularly human capital development, infra-structure strengthening, and regulatory and financing reforms, to enable sustainable local production. These findings provide a practical roadmap for policymakers, regulators, and industry leaders seeking to strengthen Nigeria’s biomanufacturing and long-term pan-demic preparedness.

28 September 2026 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
ABAnn M. Brearley
Ann M. Brearley
DTDrissa Makan Toure
Drissa Makan Toure
IBIfrah M. Biyoow
Ifrah M. Biyoow
IMInari S. Mohammed
Inari S. Mohammed
SMSusan M. Mason
Susan M. Mason
Introduction: Research emphasizing community input and participation, here termed “community-focused research,” is increasing in the health sciences literature. Maintaining a community focus may shape methodological choices around data collection, yet little is known about what types of data (primary, secondary; quantitative or qualitative) community-focused researchers use. Methods: Information on data sources and data collection methods were abstracted from the final products from five cohorts of community-focused research teams who participated in Robert Wood Johnson Foundation’s Interdisciplinary Research Leaders program between 2016 and 2023. Results: Among 53 total teams with a final product, the vast majority used primary data either alone (74%) or in combination with secondary data (21%). Of the 50 teams who conducted primary data collection, 38% collected only qualitative data, 18% collected only quantitative data, and 44% collected both quantitative and qualitative data. Conclusions: Primary data collection and qualitative methods were far more common in these community-focused research projects than in the general health sciences literature. The reasons that so many teams chose to collect primary, qualitative data are not known but may reflect a lack of existing data on communities of interest, prioritization of data collection methods that allow for greater community involvement, or research on novel topics for which there are not yet validated quantitative measurement tools. Identifying reasons for these data collection choices may identify opportunities for improving efficiency (e.g., making existing data easier to access) and/or targeting training (e.g., in qualitative data collection) to support community-focused research.